Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens

  • Alfredomaria Lurati | alfredomaria.lurati@pec.it Rheumatology Unit, Fornaroli Hospital, Magenta (MI), Italy.
  • Antonella Laria Rheumatology Unit, Fornaroli Hospital, Magenta (MI), Italy.
  • Paola Faggioli Internal Medicine Unit, Legnano Hospital, Legnano (MI), Italy.
  • Antonio Tamburello Internal Medicine Unit, Legnano Hospital, Legnano (MI), Italy.
  • Laura Castelnovo Internal Medicine Unit, Legnano Hospital, Legnano (MI), Italy.
  • Antonino Mazzone Internal Medicine Unit, Legnano Hospital, Legnano (MI), Italy.

Abstract

The bone marrow edema syndrome (BMES) is a severely disabling pain syndrome without a definite treatment and refers to transient clinical conditions with unknown pathogenic mechanism, such as transient osteoporosis of the hip, regional migratory osteoporosis, and reflex sympathetic dystrophy. Magnetic resonance imaging is used for early diagnosis and monitoring of its progression. Early differentiation from other aggressive conditions with longterm sequelae is essential in order to avoid unnecessary treatment. The aim of this monocentric trial was to test the efficacy and the safety of amino-bisphosphonate neridronate administered in two different regimens in patients with BMES. 192 patients with BMES secondary to osteoarthritis localized in the knee, hip, wrist or foot were randomly assigned to intravenous (iv) infusion of 100 mg neridronate given four times over 10 days (Group A, 72 subjects) or alternatively to iv infusions of 100 mg every 21 days over 3 months (Group B, 120 subjects). Magnetic resonance image (MRI) was performed at baseline and after 180 days. We assessed a 0-100 mm pain visual analogue scale (VAS) in each patient, too. Outcomes were MRI changes and VAS changes. A control group (35 patients) was enrolled too, treated conservatively with non-steroidal anti-inflammatory drugs and articular rest. We observed a significant improvement in MRI with the resolution of bone marrow lesions present at the baseline (P<0.01), without a significant difference between Group A and Group B. The VAS score decreased significantly during the study in both groups (P<0.05) without a significant difference between the two treatment groups (P>0.1). Both groups showed a significant clinical and radiologic improvement compared with the control group (P<0.001). In patients with BMES, the infusions of neridronate 100 mg every 21 days over 3 months or alternately every 3 days over 10 days were associated with clinically relevant and persistent benefits without significant differences between the two treatment schedules. These results provide conclusive evidence that the use of bisphosphonates, at appropriate doses, is the treatment of choice in BMES.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Sampson MJ, Kabbani M, Krishnan R, Nganga M, Theodoulou A, Krishnan J. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral bone marrow edema lesion and joint effusion in an osteoarthritic patient following pentosan polysulphate sodium treatment: a case report. BMC Mus- culoskelet Disord 2017;18:396. DOI: https://doi.org/10.1186/s12891-017-1754-3

Gao F, Sun W, Li Z, et al. Extracorporeal shock wave therapy in the treatment of primary bone edema syndrome of the knee: a prospective randomized controlled study. BMC Musculoskelet Disord 2015;16: 379. DOI: https://doi.org/10.1186/s12891-015-0837-2

Eriksen EF. Treatment of bone marrow lesions (bone marrow edema). Bonekey Rep 2015;4:755. DOI: https://doi.org/10.1038/bonekey.2015.124

Mirghasemi SA, Trepman E, Sadeghi MS, Rahimi N, Rashidinia S. Bone marrow edema syndrome in the foot and ankle. Foot Ankle Int 2016;37:1364-73. DOI: https://doi.org/10.1177/1071100716664783

Patel S. Primary bone marrow edema syndromes. Rheumatology (Oxford) 2014;53:785-92. DOI: https://doi.org/10.1093/rheumatology/ket324

Manara M, Varenna M. A clinical overview of bone marrow edema. Reumatismo 2014;66:184-96. DOI: https://doi.org/10.4081/reumatismo.2014.790

Bonadio MB, Ormond Filho AG, Helito CP, Stump XM, Demange MK. Bone marrow lesion: image, clinical presentation, and treatment. Magn Reson Insights 2017;10:1178623x17703382. DOI: https://doi.org/10.1177/1178623X17703382

Geith T, Niethammer T, Milz S, Dietrich O, Reiser M, Baur- Melnyk A. Transient bone marrow edema syndrome versus osteo-necrosis: perfusion patterns at dynamic contrast-enhanced MR imaging with high temporal resolution can allow differentiation. Radiology 2017;283:478-85. DOI: https://doi.org/10.1148/radiol.2016152665

Brunner F, Schmid A, Kissling R et al. Biphosphonates for the therapy of complex regional pain syndromeI—systematic review. Eur J Pain 2009;13:17-21. DOI: https://doi.org/10.1016/j.ejpain.2008.03.005

Huskisson EC. Measurement of pain. Lancet 1974;2:1127_31. DOI: https://doi.org/10.1016/S0140-6736(74)90884-8

Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration, Calcif Tissue Int , 1987, vol. 41 (pg. 326-33) DOI: https://doi.org/10.1007/BF02556671

Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947–95 DOI: https://doi.org/10.1056/NEJM199810013391402

Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7) DOI: https://doi.org/10.2174/1566524023362104

Varenna M, Zucchi F, Ghiringhelli D et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1477- 83)

Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of dis- traction osteogenesis. J Bone Miner Res 18(7):1300–1307 DOI: https://doi.org/10.1359/jbmr.2003.18.7.1300

Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F (2005) Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 87(3):550–557

Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG (2007) Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89(8):1727–1734 DOI: https://doi.org/10.2106/00004623-200708000-00009

Agarwala S, Jain D, Joshi VR, Sule A (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44(3):352–359 DOI: https://doi.org/10.1093/rheumatology/keh481

Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H (2006) Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273–279 DOI: https://doi.org/10.1097/01.blo.0000194078.32776.31

Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am 2005;87:550–7. DOI: https://doi.org/10.2106/00004623-200503000-00011

Aigner N, Petje G, Schneider W, Meizer R, Wlk M, Kotsaris S, et al. Bone marrow edema syndrome of the femoral head: treatment with the prostacyclin ana- logue iloprost vs. core decompression: an MRI controlled study. Wien klin Wochenschr 2005;117:130–5. DOI: https://doi.org/10.1007/s00508-005-321-3

Korompilias AV, Karantanas AH, Lykissas MG, Beris AE. Bone marrow edema syndrome. Skeletal Radiol 2009;38:425–36. DOI: https://doi.org/10.1007/s00256-008-0529-1

Ringe JD, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005;16:2063–8. DOI: https://doi.org/10.1007/s00198-005-2001-6

Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 2009;91:1013–8. DOI: https://doi.org/10.1302/0301-620X.91B8.21518

Bartl C, Imhoff A, Bartl R. Treatment of bone marrow edema syndrome with intravenous Ibandronate. Arch Orthop Trauma Surg 2012;132:1781–8. DOI: https://doi.org/10.1007/s00402-012-1617-1

Adami S, Fossaluzza V, Gatti D et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997;56:201-4.], DOI: https://doi.org/10.1136/ard.56.3.201

Varenna M, Zucchi F, Ghiringhelli D et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000;27:1477-83.

Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004;5:276-80] DOI: https://doi.org/10.1111/j.1526-4637.2004.04038.x

Manicourt DH, Brasseur JP, Boutsen Y et al. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004;50:3690-7. DOI: https://doi.org/10.1002/art.20591

M Varenna, F Zucchi, S Failoni, A Becciolini and M Berruto; Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology 2015;54:1826-1832 DOI: https://doi.org/10.1093/rheumatology/kev123

M Varenna, S Adami, M Rossini, D Gatt, L Idolazzi, F Zucchi, N Malavolta and L Sinigaglia. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology 2013;52:534-542 DOI: https://doi.org/10.1093/rheumatology/kes312

Published
2020-09-08
Info
Issue
Section
Original Articles
Keywords:
Bone marrow edema, neridronate.
Statistics
  • Abstract views: 421

  • PDF: 63
  • HTML: 0
How to Cite
Lurati, A., Laria, A., Faggioli, P., Tamburello, A., Castelnovo, L., & Mazzone, A. (2020). Neridronate in bone marrow edema syndrome. Efficacy and safety of two therapeutic regimens. Beyond Rheumatology, 2(2), 57-60. https://doi.org/10.4081/br.2020.34

Most read articles by the same author(s)